Outcome and characteristics of patients with malignant pleural effusion from differentiated thyroid carcinoma

Endocrine Journal

Koichi Ito¹  Akifumi Suzuki¹  Kenichi Matsuzu¹  Junko Akaishi¹  Fumi Saito¹  Wataru Kitagawa¹  Chisato Tomoda¹  Hiroshi Shibuya¹  Chie Masaki¹  Mitsuji Nagahama¹  Yuna Ogimi¹  Kiminori Sugino¹  Takashi Uruno¹  Keiko Ohkuwa¹ 

[1] Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan

关键词: Malignant pleural effusion;    Differentiated thyroid carcinoma;   

DOI  :  10.1507/endocrj.EJ15-0631

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(15)Cited-By(1)Metastatic differentiated thyroid carcinoma (DTC) is an uncommon cause of malignant pleural effusion (MPE) and the characteristics and clinical course have been rarely described.Herein, we report a retrospective review of the clinical course of 18 patients (15 women and 3 men) with MPE from DTC who underwent treatment at our institution between January 2005 and December 2014.MPE from DTC was diagnosed based on cytology and/or level of thyroglobulin in the pleural fluid.Pathologically, papillary carcinoma was found in 16 patients and follicular carcinoma in 2 patients.Median ages at initial diagnosis of DTC and MPE were 64 years (range, 22-79) and 74 years (range, 39-86), respectively.All patients showed radiologically apparent lung metastases, with MPE developing after 0-212 months (median, 25).In 16 patients (88.9%), other coexistent distant metastases at the time of MPE diagnosis were found in the bone (n = 10), brain (n = 5), and skin (n = 2).All patients were treated conservatively with palliative thoracentesis or chest tube drainage with or without pleurodesis.Recurrent MPE after treatment was seen in 9 patients; discharge to home health care after treatment for MPE was possible for 14 patients.The overall survival after initial diagnosis varied considerably from 14 months to 37 years, but the median survival after appearance of MPE was 10 months (range, 1-28).Systemic therapy for iodine-resistant recurrent thyroid disease may need to be considered as a treatment option for patients with MPE.

【 授权许可】

Unknown